Identification

Name
Lopinavir
Accession Number
DB01601  (EXPT00388)
Type
Small Molecule
Groups
Approved
Description

Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.

Structure
Thumb
Synonyms
  • LPV
External IDs
A-157378-0 / A-157378.0 / ABT-378
International/Other Brands
Aluviran / Koletra
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2006-04-11Not applicableUs
KaletraLopinavir (200 mg) + Ritonavir (50 mg)TabletOralAbbvie2006-09-08Not applicableCanada
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralPd Rx Pharmaceuticals, Inc.2010-06-18Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralRemedy Repack2017-01-05Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralAbbvie2010-06-18Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralDispensing Solutions, Inc.2010-06-18Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralA S Medication Solutions2010-06-182017-06-20Us
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralCardinal Health2010-06-18Not applicableUs
KaletraLopinavir (100 mg) + Ritonavir (25 mg)TabletOralAbbvie2008-08-11Not applicableCanada
KaletraLopinavir (100 mg/1) + Ritonavir (25 mg/1)Tablet, film coatedOralAbbvie2010-06-18Not applicableUs
Categories
UNII
2494G1JF75
CAS number
192725-17-0
Weight
Average: 628.8008
Monoisotopic: 628.362470666
Chemical Formula
C37H48N4O5
InChI Key
KJHKTHWMRKYKJE-SUGCFTRWSA-N
InChI
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
IUPAC Name
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES
CC(C)[[email protected]](N1CCCNC1=O)C(=O)N[[email protected]](C[[email protected]](O)[[email protected]](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1

Pharmacology

Indication

Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.

Structured Indications
Pharmacodynamics

Lopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.

Mechanism of action

Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles.

TargetActionsOrganism
AHuman immunodeficiency virus type 1 protease
inhibitor
Human immunodeficiency virus 1
Absorption

Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.

Volume of distribution
Not Available
Protein binding

Lopinavir is highly bound to plasma proteins (98-99%).

Metabolism

Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Although human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.

Affected organisms
  • Human Immunodeficiency Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Lopinavir.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lopinavir.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lopinavir.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lopinavir.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Lopinavir.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lopinavir.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Lopinavir.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lopinavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.Investigational, Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lopinavir.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Lopinavir.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lopinavir.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lopinavir.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lopinavir.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lopinavir.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Lopinavir.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Lopinavir.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Lopinavir.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Lopinavir.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Lopinavir.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Lopinavir.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Lopinavir.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Lopinavir.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Lopinavir.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lopinavir.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Lopinavir.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Lopinavir.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Lopinavir.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lopinavir.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Lopinavir.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lopinavir.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lopinavir.Approved
AmiodaroneLopinavir may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Lopinavir.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Lopinavir.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Lopinavir.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Lopinavir.Approved
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Lopinavir.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lopinavir.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lopinavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lopinavir.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Lopinavir.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Lopinavir.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Lopinavir.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lopinavir.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Lopinavir.Approved, Investigational
AprepitantThe serum concentration of Lopinavir can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Lopinavir.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Lopinavir.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Lopinavir.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Lopinavir.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Lopinavir.Approved, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Lopinavir.Investigational
AtazanavirThe metabolism of Lopinavir can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Lopinavir.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Lopinavir.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lopinavir.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Lopinavir.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Lopinavir.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lopinavir.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Lopinavir.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Lopinavir.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Lopinavir.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Lopinavir.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lopinavir.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Lopinavir.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lopinavir.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Lopinavir.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Lopinavir.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Lopinavir.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Lopinavir.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Lopinavir.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.Approved
BoceprevirThe serum concentration of Lopinavir can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Lopinavir.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lopinavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Lopinavir.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Lopinavir.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Lopinavir.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Lopinavir.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lopinavir.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lopinavir.Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lopinavir.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lopinavir.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Lopinavir.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Lopinavir.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Lopinavir.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Lopinavir.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Lopinavir.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Lopinavir.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Lopinavir.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Lopinavir.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Lopinavir.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Lopinavir.Approved
CarbamazepineThe serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Lopinavir.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Lopinavir.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lopinavir.Approved
CarisoprodolThe metabolism of Carisoprodol can be increased when combined with Lopinavir.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Lopinavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lopinavir.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Lopinavir.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Lopinavir.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lopinavir.Approved, Vet Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Lopinavir.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lopinavir.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Lopinavir.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be increased when combined with Lopinavir.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lopinavir.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Lopinavir.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Lopinavir.Investigational, Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lopinavir.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Lopinavir.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Lopinavir.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Lopinavir.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Lopinavir.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lopinavir.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Lopinavir.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Lopinavir.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lopinavir.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Lopinavir.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
ClemastineThe metabolism of Lopinavir can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lopinavir.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Lopinavir.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Lopinavir.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Lopinavir.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Lopinavir.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Lopinavir.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Lopinavir.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Lopinavir.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Lopinavir.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Lopinavir.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Lopinavir.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Lopinavir.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Lopinavir.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Lopinavir.Approved, Illicit
ClotrimazoleThe metabolism of Lopinavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Lopinavir.Approved
CobicistatThe metabolism of Lopinavir can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lopinavir.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Lopinavir.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lopinavir.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lopinavir.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Lopinavir.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Lopinavir.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Lopinavir.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Lopinavir.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Lopinavir.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Lopinavir.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Lopinavir.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.Approved
DabrafenibThe serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Lopinavir.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Lopinavir.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lopinavir.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Lopinavir.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lopinavir.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Lopinavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lopinavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Lopinavir.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Lopinavir.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Lopinavir.Approved, Investigational
DeferasiroxThe serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Lopinavir.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Lopinavir.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lopinavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lopinavir.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Lopinavir.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Lopinavir.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Lopinavir.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Lopinavir.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Lopinavir.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Lopinavir.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Lopinavir.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Lopinavir.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Lopinavir.Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Lopinavir.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lopinavir.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lopinavir.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Lopinavir.Approved, Illicit, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Lopinavir.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Lopinavir.Approved, Vet Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lopinavir.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Lopinavir.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Lopinavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lopinavir.Approved, Investigational
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Lopinavir.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.Approved, Investigational
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Lopinavir.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Lopinavir.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lopinavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lopinavir.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lopinavir.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lopinavir.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Lopinavir.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Lopinavir.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Lopinavir.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Lopinavir.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Lopinavir is combined with Disulfiram.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Lopinavir.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lopinavir.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Lopinavir.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Lopinavir.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Lopinavir.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Lopinavir.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Lopinavir.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Lopinavir.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Lopinavir.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lopinavir.Approved, Investigational
DoxycyclineThe metabolism of Lopinavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Lopinavir.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Lopinavir.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Lopinavir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lopinavir.Approved
EfavirenzThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Lopinavir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lopinavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Lopinavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Lopinavir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Lopinavir.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Lopinavir.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lopinavir.Investigational
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Lopinavir.Approved, Investigational
EnzalutamideThe serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Lopinavir.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Lopinavir.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Lopinavir.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Lopinavir.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Lopinavir.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Lopinavir.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Lopinavir.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Lopinavir.Approved
EribulinEribulin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Lopinavir.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Lopinavir.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Lopinavir.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Lopinavir.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Lopinavir.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Lopinavir.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Lopinavir.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Lopinavir.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Lopinavir.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Lopinavir.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Lopinavir.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Lopinavir.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Lopinavir.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Lopinavir.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lopinavir.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lopinavir.Approved
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Lopinavir.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Lopinavir.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Lopinavir.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Lopinavir.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Lopinavir.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lopinavir.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Lopinavir.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Lopinavir.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Lopinavir.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Lopinavir.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Lopinavir.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Lopinavir.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Lopinavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lopinavir.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Lopinavir.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Lopinavir.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Lopinavir.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.Approved
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Lopinavir.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lopinavir.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Lopinavir.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Lopinavir.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Lopinavir.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Lopinavir.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Lopinavir.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Lopinavir.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Lopinavir.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Lopinavir.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Lopinavir.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Lopinavir.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lopinavir.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Lopinavir.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
FosamprenavirThe serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lopinavir can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Lopinavir.Approved
FosphenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Lopinavir.Approved, Investigational
Fusidic AcidThe serum concentration of Lopinavir can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Lopinavir.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Lopinavir.Approved
GarlicThe serum concentration of Lopinavir can be decreased when it is combined with Garlic.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lopinavir.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Lopinavir.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Lopinavir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.Investigational, Withdrawn
GliclazideThe metabolism of Gliclazide can be increased when combined with Lopinavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Lopinavir.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be increased when combined with Lopinavir.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Lopinavir.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Lopinavir.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Lopinavir.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Lopinavir.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Lopinavir.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lopinavir.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Lopinavir.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Lopinavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Lopinavir.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Lopinavir.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Lopinavir.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Lopinavir.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Lopinavir.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Lopinavir.Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Lopinavir resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Lopinavir.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lopinavir.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Lopinavir.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Lopinavir.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.Approved
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Lopinavir.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Lopinavir.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Lopinavir.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lopinavir.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lopinavir resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Lopinavir.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Lopinavir.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Lopinavir.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Lopinavir.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Lopinavir.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Lopinavir.Approved
IndinavirThe metabolism of Lopinavir can be decreased when combined with Indinavir.Approved
IndomethacinThe metabolism of Indomethacin can be increased when combined with Lopinavir.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lopinavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lopinavir.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Lopinavir.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Lopinavir.Experimental
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Lopinavir.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Lopinavir.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Lopinavir.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Lopinavir.Investigational
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Lopinavir.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Lopinavir.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Lopinavir.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Lopinavir.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lopinavir.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Lopinavir.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Lopinavir.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Lopinavir.Approved, Investigational
KetoconazoleThe serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Lopinavir.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Lopinavir.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Lopinavir.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Lopinavir.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Lopinavir.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lopinavir.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Lopinavir.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Lopinavir.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Lopinavir.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Lopinavir.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Lopinavir.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Lopinavir.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Lopinavir.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lopinavir.Approved, Vet Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lopinavir.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Lopinavir.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Lopinavir.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Lopinavir.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Lopinavir.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Lopinavir.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Lopinavir.Approved, Investigational
LuliconazoleThe serum concentration of Lopinavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Lopinavir can be increased when combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Lopinavir.Approved
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Lopinavir.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Lopinavir.Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lopinavir.Illicit, Investigational, Withdrawn
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Lopinavir.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Lopinavir.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Lopinavir.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Lopinavir.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Lopinavir.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lopinavir.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Lopinavir.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Lopinavir.Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Lopinavir.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Lopinavir.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Lopinavir.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lopinavir.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be increased when combined with Lopinavir.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Lopinavir.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Lopinavir.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Lopinavir.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Lopinavir.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Lopinavir.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lopinavir.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Lopinavir.Illicit, Withdrawn
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Lopinavir.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Lopinavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be increased when combined with Lopinavir.Approved
Methyl salicylateThe metabolism of Methyl salicylate can be decreased when combined with Lopinavir.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lopinavir.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Lopinavir.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Lopinavir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Lopinavir.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lopinavir.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Lopinavir.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lopinavir.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Lopinavir.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lopinavir.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Lopinavir.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Lopinavir.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Lopinavir.Approved
MifepristoneThe serum concentration of Lopinavir can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lopinavir.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Lopinavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Lopinavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Lopinavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lopinavir.Approved, Investigational
MitotaneThe serum concentration of Lopinavir can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lopinavir.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Lopinavir.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Lopinavir.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Lopinavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Lopinavir.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Lopinavir.Approved, Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Lopinavir.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lopinavir.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Lopinavir.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Lopinavir.Approved, Withdrawn
NelfinavirThe serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Lopinavir.Approved, Investigational
NetupitantThe serum concentration of Lopinavir can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Lopinavir.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Lopinavir.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Lopinavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lopinavir.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be increased when combined with Lopinavir.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Lopinavir.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lopinavir.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lopinavir.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Lopinavir.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Lopinavir.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Lopinavir.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Lopinavir.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Lopinavir.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lopinavir.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Lopinavir.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Lopinavir.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Lopinavir.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Lopinavir.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Lopinavir.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Lopinavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Lopinavir.Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Lopinavir.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Lopinavir.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Lopinavir.Approved
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Lopinavir.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Lopinavir.Approved, Vet Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Lopinavir.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lopinavir.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Lopinavir.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Lopinavir.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Lopinavir.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Lopinavir.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Lopinavir.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Lopinavir.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Lopinavir.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lopinavir.Approved
PentobarbitalThe metabolism of Lopinavir can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Lopinavir.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Lopinavir.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lopinavir.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Lopinavir.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Lopinavir.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Lopinavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lopinavir.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Lopinavir.Approved, Investigational
PhenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Lopinavir.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lopinavir.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Lopinavir.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Lopinavir.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lopinavir.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Lopinavir.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lopinavir.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Lopinavir.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Lopinavir.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lopinavir.Approved
PosaconazoleThe metabolism of Lopinavir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lopinavir.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Lopinavir.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Lopinavir.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Lopinavir.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Lopinavir resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Lopinavir.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Lopinavir.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Lopinavir.Approved, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lopinavir.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.Experimental, Investigational
PrimaquineThe metabolism of Primaquine can be decreased when combined with Lopinavir.Approved
PrimidoneThe metabolism of Lopinavir can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Lopinavir.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lopinavir.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Lopinavir.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Lopinavir.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Lopinavir.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Lopinavir.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Lopinavir.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Lopinavir.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Lopinavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lopinavir.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Lopinavir.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Lopinavir.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Lopinavir.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Lopinavir.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Lopinavir.Approved, Investigational
QuinidineLopinavir may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Lopinavir.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Lopinavir.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Lopinavir.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Lopinavir.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Lopinavir.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Lopinavir.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Lopinavir.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Lopinavir.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Lopinavir.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Lopinavir.Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Lopinavir.Approved
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.Approved
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Lopinavir.Approved
RifapentineThe metabolism of Lopinavir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lopinavir.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Lopinavir.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Lopinavir.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Lopinavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Lopinavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Lopinavir.Approved, Investigational
RitonavirThe metabolism of Lopinavir can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Lopinavir.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Lopinavir.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Lopinavir.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lopinavir.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Lopinavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lopinavir.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lopinavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Lopinavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lopinavir.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Lopinavir.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Lopinavir.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Lopinavir.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Lopinavir.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Lopinavir.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Lopinavir.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Lopinavir.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Lopinavir.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Lopinavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.Approved
SiltuximabThe serum concentration of Lopinavir can be decreased when it is combined with Siltuximab.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lopinavir.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Lopinavir.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Lopinavir.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Lopinavir.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Lopinavir.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lopinavir.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lopinavir.Investigational
SotalolSotalol may increase the QTc-prolonging activities of Lopinavir.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Lopinavir.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Lopinavir.Approved
St. John's WortThe serum concentration of Lopinavir can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Lopinavir can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Lopinavir.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Lopinavir.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Lopinavir.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.Approved
SulfisoxazoleThe metabolism of Lopinavir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Lopinavir.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Lopinavir.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Lopinavir.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lopinavir.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lopinavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Lopinavir.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lopinavir resulting in a loss in efficacy.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lopinavir.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Lopinavir.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Lopinavir.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Lopinavir.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lopinavir.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Lopinavir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Lopinavir.Approved
TelithromycinThe metabolism of Lopinavir can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Lopinavir.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Lopinavir.Approved
Tenofovir disoproxilLopinavir may increase the nephrotoxic activities of Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Lopinavir.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Lopinavir.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Lopinavir.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lopinavir.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Lopinavir.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Lopinavir.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Lopinavir.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be increased when combined with Lopinavir.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lopinavir.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lopinavir.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Lopinavir.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Lopinavir.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Lopinavir.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Lopinavir.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Lopinavir.Approved
TimololThe metabolism of Timolol can be decreased when combined with Lopinavir.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Lopinavir.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lopinavir.Approved
TipranavirThe serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Lopinavir.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Lopinavir.Approved
TocilizumabThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Lopinavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.Approved
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Lopinavir.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Lopinavir.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lopinavir.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lopinavir.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Lopinavir.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Lopinavir.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Lopinavir.Approved
TrazodoneLopinavir may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Lopinavir.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Lopinavir.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Lopinavir.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Lopinavir.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Lopinavir.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Lopinavir.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Lopinavir.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Lopinavir.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Lopinavir.Approved, Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Lopinavir.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lopinavir.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Lopinavir.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Lopinavir.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Lopinavir.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Lopinavir.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Lopinavir.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Lopinavir.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Lopinavir.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Lopinavir.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Lopinavir.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Lopinavir.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Lopinavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Lopinavir.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Lopinavir.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Lopinavir.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Lopinavir.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Lopinavir.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lopinavir.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Lopinavir.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lopinavir.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Lopinavir.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lopinavir.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Lopinavir.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Lopinavir.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Lopinavir.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lopinavir.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Lopinavir.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lopinavir.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Lopinavir.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Lopinavir.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lopinavir.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Lopinavir.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Lopinavir.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Lopinavir.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Lopinavir.Approved, Investigational
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.

References

Synthesis Reference
US5914332
General References
Not Available
External Links
Human Metabolome Database
HMDB15539
KEGG Drug
D01425
KEGG Compound
C12871
PubChem Compound
92727
PubChem Substance
46508588
ChemSpider
83706
BindingDB
578
ChEBI
31781
ChEMBL
CHEMBL729
Therapeutic Targets Database
DAP000708
PharmGKB
PA450264
HET
AB1
RxList
RxList Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Lopinavir
ATC Codes
J05AR10 — Lopinavir and ritonavir
PDB Entries
1mui / 1rv7 / 2o4s / 2q5k / 2qhc / 2rkf / 2rkg / 2z54 / 3ogq / 4l1a

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedOtherHealthy Volunteers1
0CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedNot AvailableChronic Hepatitis C Infection1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Lopinavir/Ritonavir1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedOtherDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedOtherFenofibrate / Glucuronosyltransferase / Human Immunodeficiency Virus (HIV) / Hypertriglyceridemias / Protease Inhibitors1
1CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
1CompletedTreatmentChronic Hepatitis C Infection / Thrombocytopenias1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Pregnancy1
1CompletedTreatmentInsulin Resistance1
1CompletedTreatmentTuberculosis1
1SuspendedTreatmentHuman Immunodeficiency Virus (HIV)1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1, 2CompletedTreatmentInfection, Human Immunodeficiency Virus I / Pf Subclinical Parasitemia1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedTreatmentChronic Hepatitis C Infection / Fibrosis, Liver / Human Immunodeficiency Virus (HIV)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections20
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2RecruitingOtherHuman Immunodeficiency Virus (HIV) / Tuberculosis1
2TerminatedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Oligodendroglioma (AO) / Brain Stem Gliomas / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Mixed Gliomas / Neoplasms, Brain1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
2Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Viral Hepatitis B1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2WithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentAcute HIV Infection1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pediatric AIDS1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pregnancy1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHIV / AIDS / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHIV-Infected Children1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)3
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections22
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentInfection, Human Immunodeficiency Virus I2
3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3TerminatedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentAcute HIV Infection1
3Unknown StatusTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections2
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3WithdrawnTreatmentHuman Immunodeficiency Virus (HIV)1
4Active Not RecruitingTreatmentHiv-positive / Malnourished1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Proteinuria1
4CompletedBasic ScienceCardiovascular Disease (CVD) / Dyslipidemias / Glucose Metabolism Disorders / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Diseases1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
4CompletedDiagnosticAIDS-Related Opportunistic Infections / Human Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Tuberculosis1
4CompletedTreatmentHIV/AIDS Treatment / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHIV/HCV Co-infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)8
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections13
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipoatrophy1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Mitochondrial Toxicity1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)2
4RecruitingPreventionHIV/AIDS and Infections1
4RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Tuberculosis1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections7
4Unknown StatusPreventionHIV-Associated Lipodystrophy Syndrome / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections4
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableDrug Effects1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)3
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections5
Not AvailableCompletedNot AvailableInfection, Human Immunodeficiency Virus I3
Not AvailableCompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedOtherEndothelial Dysfunction1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections12
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Wasting Disease1
Not AvailableCompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentAIDS/HIV PROBLEM1
Not AvailableUnknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
Not AvailableWithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentLymphoma, Hodgkins / Stage I Adult Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
SolutionOral
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6703403Yes1996-12-262016-12-26Us
US6037157Yes1996-12-262016-12-26Us
US6232333Yes1998-05-072018-05-07Us
US7432294Yes2000-11-222020-11-22Us
US7141593Yes2000-11-222020-11-22Us
US5914332Yes1996-06-132016-06-13Us
US6284767Yes1996-08-152016-08-15Us
US7364752Yes2001-05-102021-05-10Us
US8309613Yes2005-06-242025-06-24Us
US8377952Yes2008-04-222028-04-22Us
US8691878Yes2005-02-252025-02-25Us
US8025899Yes2008-06-142028-06-14Us
US7148359Yes2000-01-192020-01-19Us
US8470347Yes2007-03-172027-03-17Us
US8268349Yes2005-02-252025-02-25Us
US8399015Yes2005-02-252025-02-25Us
US6458818Yes1998-05-072018-05-07Us
US6521651Yes1998-05-072018-05-07Us
US6911214Yes2002-05-282022-05-28Us
US8501219No2001-11-282021-11-28Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00192 mg/mLALOGPS
logP3.91ALOGPS
logP4.69ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)13.39ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area120 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity179.36 m3·mol-1ChemAxon
Polarizability69.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6593
Blood Brain Barrier-0.9916
Caco-2 permeable+0.8856
P-glycoprotein substrateSubstrate0.8755
P-glycoprotein inhibitor IInhibitor0.7355
P-glycoprotein inhibitor IIInhibitor0.5277
Renal organic cation transporterNon-inhibitor0.8578
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6732
CYP450 1A2 substrateNon-inhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.7326
CYP450 2D6 inhibitorNon-inhibitor0.9438
CYP450 2C19 inhibitorNon-inhibitor0.7983
CYP450 3A4 inhibitorNon-inhibitor0.6469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9054
Ames testNon AMES toxic0.8049
CarcinogenicityNon-carcinogens0.7865
BiodegradationNot ready biodegradable0.9182
Rat acute toxicity2.2503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8605
hERG inhibition (predictor II)Inhibitor0.8475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-0119005000-e99616dc321beea979ae
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0532-1900601000-f85a252f1640f27563a8

Taxonomy

Description
This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Valine and derivatives
Alternative Parents
Amphetamines and derivatives / m-Xylenes / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Pyrimidones / Diazinanes / N-acyl amines / Secondary carboxylic acid amides / Ureas
show 7 more
Substituents
Valine or derivatives / Amphetamine or derivatives / Phenoxy compound / Phenol ether / M-xylene / Xylene / Alkyl aryl ether / Pyrimidone / Monocyclic benzene moiety / 1,3-diazinane
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dicarboxylic acid diamide, amphetamines (CHEBI:31781)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Aspartic-type endopeptidase activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72874
Uniprot Name
Pol polyprotein
Molecular Weight
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027]
  2. Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM: Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007 Sep 6;50(18):4316-28. Epub 2007 Aug 16. [PubMed:17696512]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Authors unspecified: Lopinavir/ritonavir: a protease inhibitor combination. Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2. [PubMed:11151088]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4. [PubMed:12700464]

Drug created on August 29, 2007 12:45 / Updated on November 09, 2017 03:02